Medidata Unveils Multi-Sector Research Alliance at the 65th ASH Annual Meeting and Exposition
The Medidata Research Alliance accelerates scientific research via an academic-industry collaborative framework
New York – December 7, 2023 Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, today announced the launch of the Medidata Research Alliance. This unique consortium brings together leading clinician-researchers and key opinion leaders from academia, non-profit organizations, and the life sciences industry to leverage Medidata’s expertise in Artificial Intelligence (AI) capabilities and clinical trial data to drive cutting-edge research into innovative treatments.
The Medidata Research Alliance bridges data-driven insights into clinical practice, fostering scientific exploration that can be applied across multiple therapeutic areas.
"This initiative combines the deep expertise of physician-scientists with Medidata AI and data-driven research to help advance medical breakthroughs - ultimately supporting patients and the broader healthcare and life sciences communities,” said Fareed Melhem, SVP, Medidata AI, Medidata. “Our collective ambition is to drive medical progress by drawing insights from the volume, depth, and richness of our historical clinical trial data.”
One significant area of focus for the Research Alliance is providing a greater understanding of Chimeric antigen receptor T (CAR-T) cell therapy, a promising new therapeutic approach to treat cancer. CAR-T clinical developers face a number of challenges, including life-threatening side effects and a lack of relevant data. Medidata and academic researchers can now partner and leverage the insights from an exclusive CAR-T dataset, generated through the Medidata Data Collaboration Program. And through this effort, collaborators explore clinically impactful hypotheses and jointly conduct research that provides tangible improvements in patient care.
“It’s been a dream come true to partner with such a great group of people at Medidata and to utilize such a robust dataset to explore these hypotheses in a more granular and highly statistically powered way than a single institution may otherwise be able to,” said Theodore Scott Nowicki, MD, PhD, Assistant Professor of Pediatric Hematology/Oncology at the David Geffen School of Medicine, UCLA.
Results from the Research Alliance collaborations will be presented in poster sessions at the 65th Annual American Society of Hematology (ASH) Annual Meeting and Exposition, being held from December 9-12, 2023:
- Poster 3626: The association of phosphorus disruption and neurotoxicity in patients undergoing CAR-T therapy
- Poster 3629: Significant CRS risk model with T-cell engaging therapies
- Poster 5018: Machine learning-based decision tree for clinical management of neurotoxicity in patients undergoing CAR-T therapy
###
About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. With over 20 years of groundbreaking technological innovation across more than 30,000 trials and 9 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,100+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. The company is a wholly owned subsidiary of Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA), which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization. Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com
Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries.
Contact:
Medidata PR
Analyst Relations